Skip to main content

Table 3 Quality of life scores before and 6 months after switch from IV or IM HBIG to SC HBIG

From: Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation

DomainNBaselineEnd of studyP value*Effect size
ITaLi-Q
 Side effects8327.9 ± 27.55.5 ± 10.6< 0.00010.81
 Side effects impact8212.6 ± 19.02.3 ± 6.7< 0.00010.54
 Negative feelings8119.8 ± 25.55.7 ± 10.7< 0.00010.55
 Positive feelings8186.3 ± 18.387.0 ± 22.50.360.08
 Flexibility7931.8 ± 25.817.0 ± 14.9< 0.00010.57
 Support7552.3 ± 36.732.0 ± 27.6< 0.00010.55
 Need for support8038.7 ± 42.17.7 ± 19.0< 0.00010.74
 Satisfaction8059.6 ± 22.084.1 ± 17.1< 0.00011.11
SF-36
 Physical functioning8576.2 ± 22.878.2 ± 24.00.050.09
 Role physical8164.8 ± 41.075.0 ± 39.70.030.25
 Pain8671.7 ± 24.683.9 ± 23.1<.00010.50
 General health8451.8 ± 24.050.8 ± 23.60.930.04
 Vitality8357.4 ± 20.358.6 ± 18.20.130.06
 Social functioning8673.8 ± 22.782.8 ± 20.9< 0.00010.40
 Role emotional8166.7 ± 42.178.6 ± 37.40.0050.28
 Mental health8366.0 ± 19.367.0 ± 17.90.390.05
 Physical component summary score7545.7 ± 8.948.1 ± 8.30.0020.27
 Mental component summary score7546.3 ± 10.748.2 ± 9.50.0070.18
  1. HBIG hepatitis B immunoglobulin, IM intramuscular, ITaLi-Q Immunoglobulin Therapy after Liver transplantation Questionnaire, IV intravenous, SC subcutaneous
  2. * Wilcoxon signed ranks test